1. Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
- Author
-
Roberto Buonaiuto, Giuseppe Neola, Sabrina Chiara Cecere, Aldo Caltavituro, Amedeo Cefaliello, Erica Pietroluongo, Pietro De Placido, Mario Giuliano, Grazia Arpino, and Carmine De Angelis
- Subjects
ovarian cancer ,glucocorticoid receptor ,glucocorticoids ,chemotherapy resistance ,Microbiology ,QR1-502 - Abstract
Ovarian cancer (OC) is the leading cause of death from gynecological malignancies worldwide. Fortunately, recent advances in OC biology and the discovery of novel therapeutic targets have led to the development of novel therapeutic agents that may improve the outcome of OC patients. The glucocorticoid receptor (GR) is a ligand-dependent transcriptional factor known for its role in body stress reactions, energy homeostasis and immune regulation. Notably, evidence suggests that GR may play a relevant role in tumor progression and may affect treatment response. In cell culture models, administration of low levels of glucocorticoids (GCs) suppresses OC growth and metastasis. Conversely, high GR expression has been associated with poor prognostic features and long-term outcomes in patients with OC. Moreover, both preclinical and clinical data have shown that GR activation impairs the effectiveness of chemotherapy by inducing the apoptotic pathways and cell differentiation. In this narrative review, we summarize data related to the function and role of GR in OC. To this aim, we reorganized the controversial and fragmented data regarding GR activity in OC and herein describe its potential use as a prognostic and predictive biomarker. Moreover, we explored the interplay between GR and BRCA expression and reviewed the latest therapeutic strategies such as non-selective GR antagonists and selective GR modulators to enhance chemotherapy sensitivity, and to finally provide new treatment options in OC patients.
- Published
- 2023
- Full Text
- View/download PDF